Conference Coverage

Finally, immunotherapy shows benefit in TNBC

MUNICH – Adding atezolizumab to nab-paclitaxel improved progression-free and overall survival in patients with PD-L1 positive triple-negative...

From the Journals

Kymriah appears cost effective in analysis

The latest study on the CAR T therapy tisagenlecleucel for pediatric leukemia says it may be cost effective, provided that the long-term benefits...